Innoviva Inc (INVA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $21.14 (+0.43%), Market cap $1.62B, P/E ratio 3.51, 52-week low–high $16.67 ~ $24.24.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated
Financial statements, price targets, institutional (13F) holdings and related news for Innoviva Inc are updated in real time on BlackAll Trade.
Innoviva Inc trades at $21.14 (+0.43%). Real-time quotes and charts are available on BlackAll Trade.
Innoviva Inc has a market cap of about $1.62B. Its P/E ratio is 3.51.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a L